



Alectinib (Alecensa®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab
Zweitlinientherapie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Hermann Einsele

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Alectinib, NSCLC, ALK+, second line	2
--	----------


Alectinib (Alecensa®)

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » ab Zweitlinientherapie

Stand: Juli 2021

1 Alectinib, NSCLC, ALK+, second line

Alectinib, NSCLC, ALK+, second line																																																																											
	Facts	Appraisal	EU Approval 2017																																																																								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Parameter</th> <th style="text-align: left;">Results¹⁴</th> <th style="text-align: left;">HR¹⁵</th> <th style="text-align: left;">p value</th> </tr> </thead> <tbody> <tr> <td>RR²</td> <td>2.9 vs 37.5</td> <td></td> <td></td> </tr> <tr> <td>PFS³</td> <td>1.4 vs 9.6</td> <td>0.15</td> <td>p < 0.001</td> </tr> <tr> <td>OS⁵</td> <td>n.r.¹⁸ vs 12.6</td> <td></td> <td>n.s.¹⁶</td> </tr> <tr> <td>SAE⁷</td> <td>42.1 vs 27.1</td> <td></td> <td></td> </tr> </tbody> </table> <p>Remarks: 62.9% of patients in the control arm received Alectinib at a later stage (crossover/switching).</p>	Parameter	Results ¹⁴	HR ¹⁵	p value	RR ²	2.9 vs 37.5			PFS ³	1.4 vs 9.6	0.15	p < 0.001	OS ⁵	n.r. ¹⁸ vs 12.6		n.s. ¹⁶	SAE ⁷	42.1 vs 27.1			<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Evidence (LoE)</th> <th>5</th> <th>4</th> <th>3b</th> <th>3a</th> <th>2c</th> <th>2b</th> <th>2a</th> <th>1b</th> <th>1a</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Clinical benefit (ESMO MCBS)</th> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> </tr> </thead> <tbody> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table> <p> ■ curative ■ non-curative </p>	Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a											Clinical benefit (ESMO MCBS)	1	2	3	4	5							<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Additional benefit (G-BA)</th> <th>lower</th> <th>proven</th> <th>not quantifiable</th> <th>not minor</th> <th>considerable</th> <th>major</th> </tr> </thead> <tbody> <tr> <td>suitable for other systemic treatment²⁹</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>not suitable for other systemic treatment³⁰</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </tbody> </table>	Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major	suitable for other systemic treatment ²⁹							not suitable for other systemic treatment ³⁰						
Parameter	Results ¹⁴	HR ¹⁵	p value																																																																								
RR ²	2.9 vs 37.5																																																																										
PFS ³	1.4 vs 9.6	0.15	p < 0.001																																																																								
OS ⁵	n.r. ¹⁸ vs 12.6		n.s. ¹⁶																																																																								
SAE ⁷	42.1 vs 27.1																																																																										
Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a																																																																		
Clinical benefit (ESMO MCBS)	1	2	3	4	5																																																																						
Additional benefit (G-BA)	lower	proven	not quantifiable	not minor	considerable	major																																																																					
suitable for other systemic treatment ²⁹																																																																											
not suitable for other systemic treatment ³⁰																																																																											
<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td>Patients</td> <td>ALK+, after Crizotinib</td> </tr> <tr> <td>Trial</td> <td>ALUR, phase 3</td> </tr> <tr> <td>Randomisation</td> <td>1 : 1</td> </tr> <tr> <td>N¹</td> <td>107</td> </tr> <tr> <td>New Therapy</td> <td>Alectinib</td> </tr> <tr> <td>Control</td> <td>Docetaxel or Pemetrexed</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1093/annonc/mdy121</td> </tr> </tbody> </table>	Patients	ALK+, after Crizotinib	Trial	ALUR, phase 3	Randomisation	1 : 1	N¹	107	New Therapy	Alectinib	Control	Docetaxel or Pemetrexed	Publication	DOI:10.1093/annonc/mdy121																																																													
Patients	ALK+, after Crizotinib																																																																										
Trial	ALUR, phase 3																																																																										
Randomisation	1 : 1																																																																										
N¹	107																																																																										
New Therapy	Alectinib																																																																										
Control	Docetaxel or Pemetrexed																																																																										
Publication	DOI:10.1093/annonc/mdy121																																																																										

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy

¹⁶ n. s. not significant

¹⁸ n. r. - median not reached

²⁹ Pemetrexed, Docetaxel or Ceritinib

³⁰ Pemetrexed, Docetaxel or Ceritinib